Glucagon-like peptide-1 and energy homeostasis

被引:39
|
作者
Burcelin, Remy [1 ]
Cani, Patrice D.
Knauf, Claude
机构
[1] Univ Toulouse 3, Inst Mol Med Rangueil I2MR, INSERM 858, IFR 31,CHU Rangueil, F-31432 Toulouse 4, France
[2] Catholic Univ Louvain, Unit Pharmacokinet Metab Nutr & Toxicol, B-1200 Brussels, Belgium
来源
JOURNAL OF NUTRITION | 2007年 / 137卷 / 11期
关键词
D O I
10.1093/jn/137.11.2534S
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
A growing body of evidence demonstrates the role of gut-derived hormones in the control of energy homeostasis. Among those intestinal signals, physiological and therapeutic interest has been drawn to glucagon-like peptide-1 (GLP-1). The main reasons are that this hormone 1) is secreted by epithelial intestinal L-cells in response to glucose and lipids, 2) enhances glucose-stimulated insulin secretion, 3) improves blood glucose profiles of type 2 diabetic patients by means of several actions on pancreatic hormone secretions, 4) reduces body weight and food intake, and 5) slows gastric emptying. Furthermore, recent evidence has suggested that the nervous system is a key player accounting for the beneficial role of GLP-l on the control of energy homeostasis. Hence, the role of GLP-1 on the gut-to-brain axis is reviewed.
引用
收藏
页码:2534S / 2538S
页数:5
相关论文
共 50 条
  • [21] Glucagon, glucagon-like peptide-1 and their receptors: An introduction
    Holst, JJ
    ACTA PHYSIOLOGICA SCANDINAVICA, 1996, 157 (03): : 309 - 315
  • [22] EFFECT OF GLUCAGON ON SECRETION OF GLUCAGON-LIKE PEPTIDE-1
    SHIMA, K
    OHBOSHI, C
    SATO, M
    HIROTA, M
    HORMONE AND METABOLIC RESEARCH, 1988, 20 (02) : 123 - 124
  • [23] Ghrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis
    Lopes, Karynne Grutter
    da Silva Junior, Vicente Lopes
    Marques Lopes, Fernanda de Azevedo
    Bouskela, Eliete
    Coelho de Souza, Maria das Gracas
    Kraemer-Aguiar, Luiz Guilherme
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2023, 67 (04):
  • [24] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [25] Glucagon-Like Peptide-1 Receptor Agonists
    Edelman, Steven V.
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S12 - S16
  • [26] Glucagon-like peptide-1, a matter of taste?
    Jensterle, Mojca
    DeVries, J. Hans
    Battelino, Tadej
    Battelino, Saba
    Yildiz, Bulent
    Janez, Andrej
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04): : 763 - 775
  • [27] Is ghrelin a glucagon-like peptide-1 secretagogue?
    Ueno, Hiroaki
    Nakazato, Masamitsu
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 466 - 467
  • [28] Glucagon-Like Peptide-1 Gene Therapy
    Rowzee, Anne M.
    Cawley, Niamh X.
    Chiorini, John A.
    Di Pasquale, Giovanni
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [29] Glucagon-like peptide-1 and safety - Reply
    Bloom, SR
    NATURE, 1997, 385 (6613) : 214 - 214
  • [30] Glucagon-Like Peptide-1 and Diabetes 2012
    Monami, Matteo
    Di Pasquale, Giovanni
    Rowzee, Anna
    Rotella, Carlo Maria
    Mannucci, Edoardo
    EXPERIMENTAL DIABETES RESEARCH, 2012,